Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›
Research›
Non-Profits›
The Leukemia & Lymphoma Society's Therapy Acceleration Program
AddedMar 20, 2024
UpdatedJun 28, 2026
The Leukemia & Lymphoma Society's Therapy Acceleration Program

The Leukemia & Lymphoma Society's Therapy Acceleration Program

Operating

Accelerating blood cancer therapeutics in NYC.

Location
New York City, NY, US
Overview
Compare
Employees
Website

The Leukemia & Lymphoma Society's Therapy Acceleration Program (TAP) is a strategic venture philanthropy initiative founded to accelerate the development of innovative blood cancer therapeutics. Based in New York City, TAP's core mission is to change the standard of care for blood cancer patients while generating a return on investment for the Leukemia & Lymphoma Society's broader mission. TAP focuses on funding and supporting the development of novel treatments that have the potential to significantly improve patient outcomes.

Notable affiliated people include former TAP partners like X4 Pharmaceuticals, which achieved FDA approval for Mavorixafor, a treatment for WHIM syndrome. TAP's key achievements include advancing multiple therapeutic candidates through critical stages of development, thereby impacting the lives of blood cancer patients. The program has made significant strides in the medical field by fostering innovation and expediting the availability of life-saving treatments.

Quick Facts

Where is The Leukemia & Lymphoma Society's Therapy Acceleration Program's headquarters located?

The Leukemia & Lymphoma Society's Therapy Acceleration Program's headquarters is located in New York City, NY, US.

How many employees does The Leukemia & Lymphoma Society's Therapy Acceleration Program have?

The Leukemia & Lymphoma Society's Therapy Acceleration Program has 50 employees as of Feb 4, 2024.

Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Customer
  • Enterprise
  • Non-Profit
Main Product
  • Medical Research
Tags
  • Financial
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 813000Religious, Grantmaking, Civic, Professional, and Similar Organizations
  • 813900Business, Professional, Labor, Political, and Similar Organizations
  • 813920Professional Organizations
  • 810000Other Services (except Public Administration)
SIC
  • 8600Membership Organizations
  • 8690Membership Organizations, Not Elsewhere Classified